The Claim
Long-term TRIAC therapy in adults with resistance to thyroid hormone β is associated with no significant changes in total cholesterol, triglycerides, fasting glucose, insulin resistance, or bone mineral density.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with resistance to thyroid hormone β, long-term TRIAC therapy does not change total cholesterol, triglycerides, fasting glucose, insulin resistance, or bone mineral density.
See the scientific wording
In adults with resistance to thyroid hormone β, TRIAC therapy is associated with no significant changes in total cholesterol, triglycerides, fasting glucose, insulin resistance, or bone mineral density after long-term use (up to 143 months), suggesting it does not worsen metabolic or skeletal complications of the disorder.
TRIAC activates thyroid hormone receptors in the brain, which tells the pituitary to stop signaling the thyroid gland to produce excess hormones. This lowers the amount of thyroid hormone in the blood, which reduces overactivity in the liver, muscles, and heart. As a result, the body's energy use drops to normal levels, and metabolic markers like cholesterol, triglycerides, and blood sugar stay stable without causing bone loss.
What the research says
1 studyIn people with a rare thyroid condition, taking TRIAC for many years didn’t make their cholesterol or blood sugar worse, and they didn’t have any bad side effects—so it seems safe for their metabolism and bones over the long term.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.